Amerise Biosciences Limited (BOM:531681)

Amerise Biosciences Income Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Operating Revenue	-	-	-	90.08	-
Other Revenue	1.88	0.36	0.09	5.69	-1.69
Revenue	1.88	0.36	0.09	95.77	-1.69
Revenue Growth (YoY)	423.68%	307.95%	-99.91%	-	-
Cost of Revenue	-	-	-	89.15	-
Gross Profit	1.88	0.36	0.09	6.63	-1.69
Selling, General & Admin	1.02	0.89	0.2	0.53	0.47
Other Operating Expenses	0.79	0.93	1.54	0.6	0.63
Operating Expenses	1.81	1.82	1.75	1.13	1.68
Operating Income	0.08	-1.46	-1.66	5.5	-3.37
Other Non Operating Income (Expenses)	0	-0	-0	-0	-
EBT Excluding Unusual Items	0.08	-1.46	-1.66	5.49	-3.37
Pretax Income	0.08	-1.46	-1.66	5.49	-3.37
Income Tax Expense	0.02	-	-0.47	-	-
Net Income	0.06	-1.46	-1.19	5.49	-3.37
Net Income to Common	0.06	-1.46	-1.19	5.49	-3.37
Shares Outstanding (Basic)	53	66	66	66	66
Shares Outstanding (Diluted)	53	66	66	66	66
Shares Change (YoY)	-19.86%	-	-	-	-
EPS (Basic)	0.00	-0.02	-0.02	0.08	-0.05
EPS (Diluted)	0.00	-0.02	-0.02	0.08	-0.05
Gross Margin	100.00%	100.00%	100.00%	6.92%	-
Operating Margin	3.99%	-405.85%	-1884.09%	5.74%	-
Profit Margin	3.03%	-406.96%	-1351.14%	5.73%	-
EBIT	0.08	-1.46	-1.66	5.5	-3.37
EBIT Margin	3.99%	-	-	5.74%	-
Effective Tax Rate	25.00%	-	-	-	-
Revenue as Reported	1.88	0.36	0.09	95.77	-1.69

Source: S&P Global Market Intelligence. Standard template. Financial Sources.